Evidence map›Paper›PMID 35609027›Full record

ArticlePloS one2022

The SARS-CoV-2 main protease doesn't induce cell death in human cells in vitro.

Alexey Komissarov, Maria Karaseva, Marina Roschina, Sergey Kostrov, Ilya Demidyuk

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alexey KomissarovInstitute of Molecular Genetics of National Research Centre Kurchatov Institute, Moscow, Russian Federation.ORCID 0000-0003-1018-5195
Maria KarasevaInstitute of Molecular Genetics of National Research Centre Kurchatov Institute, Moscow, Russian Federation.
Marina RoschinaInstitute of Molecular Genetics of National Research Centre Kurchatov Institute, Moscow, Russian Federation.
Sergey KostrovInstitute of Molecular Genetics of National Research Centre Kurchatov Institute, Moscow, Russian Federation.
Ilya DemidyukInstitute of Molecular Genetics of National Research Centre Kurchatov Institute, Moscow, Russian Federation.
Kurchatov Institute · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19) which has extremely rapidly spread worldwide. In order to develop the effective antiviral therapies, it is required to understand the molecular mechanisms of the SARS-CoV-2 pathogenesis. The main protease, or 3C-like protease (3CLpro), plays the essential role in the coronavirus replication that makes the enzyme a promising therapeutic target. Viral enzymes are known to be multifunctional. Particularly, 3CLpro of SARS-CoV was shown to induce apoptosis in addition to its main function. In the present study we analyzed the cytotoxicity of active SARS-CoV-2 3CLpro and its inactivated form upon their individual expression in four human cell lines. For this purpose, we constructed a protein biosensor which allows to detect the proteolytic activity of SARS-CoV-2 3CLpro and confirmed the expression of the active protease in all cell lines used. We studied viability and morphology of the cells and found that both active and inactivated enzyme variants induce no cell death in contrast to the homologous 3CL protease of SARS-CoV. These results indicate that SARS-CoV-2 3CLpro is unlikely contribute to the cytopathic effect observed during viral infection directly.

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsCell DeathCoronavirus 3C ProteasesHumansPeptide HydrolasesProtease Inhibitors3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesPeptide HydrolasesProtease Inhibitors

Identifiers

PMID35609027
PMCPMC9129031
OpenAlexW4281399979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.